
Eikon Therapeutics, Inc. (NASDAQ:EIKN – Free Report) – Research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Eikon Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst S. Nik now expects that the company will post earnings per share of ($7.11) for the year, up from their prior estimate of ($7.40). HC Wainwright currently has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Eikon Therapeutics’ current full-year earnings is ($7.04) per share. HC Wainwright also issued estimates for Eikon Therapeutics’ Q4 2026 earnings at ($1.69) EPS and FY2027 earnings at ($7.50) EPS.
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15.
A number of other brokerages have also recently weighed in on EIKN. Wedbush reduced their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research note on Friday, August 14th. Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. Wall Street Zen upgraded shares of Eikon Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Mizuho raised shares of Eikon Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Eikon Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.
Check Out Our Latest Analysis on EIKN
Eikon Therapeutics Trading Down 9.9%
Shares of EIKN stock opened at $5.39 on Monday. Eikon Therapeutics has a 12 month low of $5.01 and a 12 month high of $17.40. The business’s 50 day moving average is $7.42 and its two-hundred day moving average is $10.02.
Insider Buying and Selling at Eikon Therapeutics
In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $11.56 per share, for a total transaction of $1,031,152.00. Following the purchase, the insider directly owned 89,200 shares in the company, valued at $1,031,152. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Institutional Trading of Eikon Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after buying an additional 962,046 shares during the last quarter. Regents of The University of California bought a new stake in shares of Eikon Therapeutics in the third quarter valued at approximately $5,106,000. State Street Corp grew its stake in shares of Eikon Therapeutics by 71.9% in the third quarter. State Street Corp now owns 608,838 shares of the company’s stock worth $4,895,000 after acquiring an additional 254,745 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of Eikon Therapeutics in the second quarter worth $3,341,000. Finally, Comprehensive Financial Management LLC acquired a new stake in shares of Eikon Therapeutics in the second quarter worth $1,517,000.
Eikon Therapeutics Company Profile
Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.
Recommended Stories
- Five stocks we like better than Eikon Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
